Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model

Lung cancer patients with mutations in epidermal growth factor receptor (EGFR) benefit from treatments targeting tyrosine kinase inhibitors (TKIs). However, both intrinsic and acquired resistance of tumors to TKIs are common, and EGFR variants have been identified that are resistant to multiple TKIs...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarcar, Bhaswati, Gimbrone, Nicholas T., Wright, Gabriela, Remsing Rix, Lily L., Gordian, Edna R., Rix, Uwe, Chiappori, Alberto A., Reuther, Gary W., Santiago‐Cardona, Pedro G., Muñoz‐Antonia, Teresita, Cress, William Douglas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768113/
https://www.ncbi.nlm.nih.gov/pubmed/31314158
http://dx.doi.org/10.1002/2211-5463.12702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768113/
https://www.ncbi.nlm.nih.gov/pubmed/31314158
http://dx.doi.org/10.1002/2211-5463.12702

Ejemplares similares